The management team is welcoming two new members, Christina Erixon, Head of Pharmaceutical Development & Operations, who is replacing Agneta Larhed, and Robert Ehrl, Head of Supply, who is taking over from Jesper Lind.
Both roles have been expanded from part-time consultants to full-time positions.
Agneta Larhed is leaving the executive team but will remain a part-time consultant to the company with unchanged scope. Jesper Lind will also remain as a consultant to the company for a period.
“First and foremost, I want to thank Agneta and Jesper for their outstanding contributions to Moberg Pharma and their contributions to the executive team. As part of our growth journey, I now welcome Christina and Robert to the Moberg Pharma executive team. Both Christina’s extensive experience in the development of new drugs and Robert’s extensive production experience will be highly valuable to the company,” says Anna Ljung, CEO of Moberg Pharma AB.
Christina Erixon has a broad experience of development, regulatory and quality within the pharmaceutical industry. Dr. Erixon has held leading positions within the pharmaceutical industry and at regulatory authorities, including roles as the manager of clinical trials at the Swedish Medical Products Agency, senior product developer at AstraZeneca, business manager and associate director for Pharmaceutical Development at APL, and most recently as the director of Drug Development at SDS Life Science. Dr. Erixon is a pharmacist with a doctoral degree in pharmaceutics from Uppsala University.
Robert Ehrl holds a Ph.D. in organic chemist with over 20 years of experience in the pharmaceutical industry. He has held leadership positions at AstraZeneca and Valneva Sweden AB, primarily in process development, supply, and manufacturing. Dr. Ehrl has worked with both small molecule and biological drugs/vaccines, from active pharmaceutical ingredient (API) to final packed product.
Photo: Moberg Pharma lab